-
Story
Community health takes a village: from Pulpit to Pew -
Story
American Chemical Society honors Novartis researchers -
Press Release
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
-
Story
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond -
Press Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
-
Press Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
-
Story
Working with communities to close gaps in heart disease and cancer care -
Press Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
-
Story
Managing Quality of Life with CML -
Press Release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
-
Story
Bringing proteins together to take cancer apart -
Press Release
Novartis announces plans to build flagship manufacturing hub in North Carolina